HUNENBERG, Switzerland--(BUSINESS WIRE)--Dec. 12, 2005--Alcon, Inc. (NYSE:ACL) announced today that the Australian Therapeutic Goods Administration (TGA) has approved RETAANE(R) suspension (15mg anecortave acetate suspension) for the treatment of subfoveal choroidal neovascularization (CNV) due to exudative age-related macular degeneration (AMD) where there is a classic component.
